Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt Abeta aggregates

International Journal of Pharmaceutics

Volumn 526, Issue 1-2, 2017, Pages 413-424

  Barbara, Ruozi ^a   Belletti, Daniela ^a   Pederzoli, Francesca ^a   Masoni, Martina ^a   Keller, Johannes ^b   Ballestrazzi, Antonio ^a   Vandelli, Maria Angela ^a   Tosi, Giovanni ^a   Grabrucker, Andreas M ^b,c  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

Alzheimer's disease; Amyloid; BBB targeting nanoparticles; Curcumin; Nanotechnology; Synapse

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CURCUMIN; POLYGLACTIN; AMYLOID BETA PROTEIN; NANOPARTICLE;

ALZHEIMER DISEASE; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; BRAIN CELL CULTURE; CONTROLLED STUDY; EMBRYO; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT; CHEMISTRY; DRUG EFFECTS; HUMAN; TRANSPORT AT THE CELLULAR LEVEL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CURCUMIN; HUMANS; NANOPARTICLES;

EID: 85019185474     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2017.05.015     Document Type: Article

References (50)

1. Abbott, N.J., Patabendige, A.A.K., Dolman, D.E.M., Yusof, S.R., Begley, D.J., Structure and function of the Blood–brain barrier. Neurobiol. Dis. 37 (2010), 13–25.
2. Anand, P., Kunnumakkara, A.B., Newman, R.A., Aggarwal, B.B., Bioavailability of curcumin: problems and promises. Mol. Pharm. 4 (2007), 807–818.
3. Baum, L., Ng, A., Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J. Alzheimers Dis. 6 (2004), 367–377.
4. Bondioli, L., Costantino, L., Ballestrazzi, A., Lucchesi, D., Boraschi, D., Pellati, F., Benvenuti, S., Tosi, G., Vandelli, M.A., PLGA nanoparticles surface decorated with the sialic acid N-acetylneuraminic acid. Biomaterials 31 (2010), 3395–3403.
5. Butterfield, D.A., Beta-Amyloid-Associated free radical oxidative stress and neurotoxicity: implications for alzheimer's disease. Chem. Res. Toxicol. 10 (1997), 495–506.
6. Butters, N., Granholm, E., Salmon, D.P., Grant, I., Wolfe, J., Episodic and semantic memory: a comparison of amnesic and demented patients. J. Clin. Exp. Neuropsychol. 9 (1987), 479–497.
7. Costantino, L., Gandolfi, F., Tosi, G., Rivasi, F., Vandelli, M.A., Forni, F., Peptidederivatized biodegradable nanoparticles able to cross the blood-brain barrier. J. Control. Release 108 (2005), 84–96.
8. Esatbeyoglu, T., Huebbe, P., Ernst, I.M.A., Chin, D., Wagner, A.E., Rimbach, G., Curcumin − vom molekül zur biologischen wirkung. Angew. Chem. 124 (2012), 5402–5427.
9. Gallo, J.M., Noble, W., Martin, T.R., RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies. Cell Mol. Life Sci. 64 (2007), 1701–1714.
10. Goozee, K.G., Shah, T.M., Sohrabi, H.R., Rainey-Smith, S.R., Brown, B., Verdile, G., Martins, R.N., Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer's disease. Br. J. Nutr. 115 (2016), 449–465.
11. Grabrucker, A., Vaida, B., Bockmann, J., Boeckers, T.M., Synaptogenesis of hippocampal neurons in primary cell culture. Cell Tissue Res. 338 (2009), 333–341.
12. Grabrucker, A.M., Garner, C.C., Boeckers, T.M., Bondioli, L., Ruozi, B., Forni, F., Vandelli, M.A., Tosi, G., Development of novel Zn2+ loaded nanoparticles designed for cell type targeted drug release in CNS neurons: in vitro evidences. PLoS One, 6, 2011, e17851.
13. Grabrucker, A.M., Schmeisser, M.J., Udvardi, P.T., Arons, M., Schoen, M., Woodling, N.S., Andreasson, K.I., Hof, P.R., Buxbaum, J.D., Garner, C.C., Boeckers, T.M., Amyloid beta protein-induced zinc sequestration leads to synaptic loss via dysregulation of the ProSAP2/Shank3 scaffold. Mol. Neurodegener., 6, 2011, 65.
14. Grabrucker, A.M., Ruozi, B., Belletti, D., Pederzoli, F., Forni, F., Vandelli, M.A., Tosi, G., Nanoparticle transport across the blood brain barrier. Tissue Barriers, 4, 2016, e1153568.
15. Hussain, Z., Thu, H.E., Ng, S.F., Khan, S., Katas, H., Nanoencapsulation, an efficient and promising approach to maximize wound healing efficacy of curcumin: a review of new trends and state-of-the-art. Colloids Surf. B Biointerfaces, 2017, 10.1016/j.colsurfb.2016.11.036.
16. Joshi, D.P., Lan-Chun-Fung, Y.L., Pritchard, J.G., Determination of poly(vinyl alcohol) via its complex with boric acid and iodine. Anal. Chim. Acta 104 (1979), 153–160.
17. Kasinski, A.L., Du, Y., Thomas, S.L., Zhao, J., Sun, S.Y., Khuri, F.R., Wang, C.Y., Shoji, M., Sun, A., Snyder, J.P., Liotta, D., Fu, H., Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol. Pharmacol. 74 (2008), 654–661.
18. Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C.W., Necula, M., Margol, L., Wu, J., Breydo, L., Thompson, J.L., Rasool, S., Gurlo, T., Butler, P., Glabe, C.G., Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener., 2, 2007, 18.
19. Klinger, N.V., Mittal, S., Therapeutic potential of curcumin for the treatment of brain tumors. Oxid. Med. Cell. Longev., 2016, 2016, 9324085.
20. Kumar, S., Walter, J., Phosphorylation of amyloid beta (A() peptides − a trigger for formation of toxic aggregates in alzheimer's disease. Aging (Milano) 3 (2011), 803–812.
21. Lazar, A.N., Mourtas, S., Youssef, I., Parizot, C., Dauphin, A., Delatour, B., Antimisiaris, S.G., Duyckaerts, C., Curcumin-conjugated nanoliposomes with high affinity for Aβ deposits: possible applications to Alzheimer disease. Nanomedicine 9 (2013), 712–721.
22. Lin, J.K., Chen, Y.C., Huang, Y.T., Lin-Shiau, S.Y., Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin. J. Cell Biochem. 67 (1997), 39–48.
23. Mainardes, R.M., Evangelista, R.C., Praziquantel-loaded PLGA nanoparticles: preparation and characterization. J. Microencapsul. 22 (2005), 13–24.
24. Mathew, A., Fukuda, T., Nagaoka, Y., Hasumura, T., Morimoto, H., Yoshida, Y., Maekawa, T., Venugopal, K., Kumar, D.S., Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. PLoS One, 7, 2012, e32616.
25. Mishra, S., Palanivelu, K., The effect of curcumin (turmeric) on Alzheimer's disease: an overview. Ann. Indian. Acad. Neurol. 11 (2008), 13–19.
26. Mulik, R.S., Mönkkönen, J., Juvonen, R.O., Mahadik, K.R., Paradkar, A.R., ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol. Pharm. 7 (2012), 815–825.
27. Mundargi, R.C., Babu, V.R., Rangaswamy, V., Patel, P., Aminabhavi, T.M., Nano/micro technologies for delivering macromolecular therapeutics using poly(D: L-lactide-co-glycolide) and its derivatives. J. Control. Release 125 (2008), 193–209.
28. Perl, D.P., Neuropathology of alzheimer's disease. Mt. Sinai J. Med. 77 (2010), 32–42.
29. Radic, S., Davis, T.P., Ke, P.C., Ding, F., Contrasting effects of nanoparticle?protein attraction on amyloid aggregation. RSC Adv. 5 (2015), 105489–105498.
30. Rajeswari, A., Curcumin protects mouse brain from oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Eur. Rev. Med. Pharmacol. Sci. 10 (2006), 157–161.
31. Ratner, B.D., Castner, D.G., Electron Spectroscopy for Chemical Analysis, in Surface Analysis − The Principal Techniques. Vickerman, J.C., Gilmore, I.S., (eds.), 2nd ed., 2009, John Wiley & Sons, Ltd, Chichester, UK.
32. Ray, B., Lahiri, D.K., Neuroinflammation in alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Curr. Opin. Pharmacol. 9 (2009), 434–444.
33. Salvalaio, M., Rigon, L., Belletti, D., D'Avanzo, F., Pederzoli, F., Ruozi, B., Marin, O., Vandelli, M.A., Forni, F., Scarpa, M., Tomanin, R., Tosi, G., Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in lysosomal storage disorders. PLoS One, 11, 2016, e0156452.
34. Salvesen, G.S., Duckett, C.S., Iap proteins: blocking the road to death ' S door. Nat. Rev. Mol. Cell Biol., 3, 2002, 401-410.
35. Schellenberg, G.D., Montine, T.J., The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol. 124 (2012), 305–323.
36. Schmeisser, M.J., Ey, E., Wegener, S., Bockmann, J., Stempel, A.V., Kuebler, A., Janssen, A.L., Udvardi, P.T., Shiban, E., Spilker, C., Balschun, D., Skryabin, B.V., Dieck, St., Smalla, K.H., Montag, D., Leblond, C.S., Faure, P., Torquet, N., Le Sourd, A.M., Toro, R., Grabrucker, A.M., Shoichet, S.A., Schmitz, D., Kreutz, M.R., Bourgeron, T., Gundelfinger, E.D., Boeckers, T.M., Autistic-like behaviours and hyperactivity in mice lacking ProSAP1/Shank2. Nature 486 (2012), 256–260.
37. Subramani, P.A., Panati, K., Narala, V.R., Curcumin nanotechnologies and its anticancer activity. Nutr. Cancer 69 (2017), 381–393.
38. Tosi, G., Costantino, L., Rivasi, F., Ruozi, B., Leo, E., Vergoni, A.V., Tacchi, R., Bertolini, A., Vandelli, M.A., Forni, F., Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J. Control. Release 122 (2007), 1–9.
39. Tosi, G., Costantino, L., Ruozi, B., Forni, F., Vandelli, M.A., Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin. Drug Deliv. 5 (2008), 155–174.
40. Tosi, G., Vergoni, A.V., Ruozi, B., Bondioli, L., Badiali, L., Rivasi, F., Costantino, L., Forni, F., Vandelli, M.A., Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: in vivo pharmacological evidence and biodistribution. J. Control. Release 145 (2010), 49–57.
41. Tosi, G., Fano, R.A., Bondioli, L., Badiali, L., Benassi, R., Rivasi, F., Ruozi, B., Forni, F., Vandelli, M.A., Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. Nanomedicine 6 (2011), 423–436.
42. Tosi, G., Ruozi, B., Belletti, D., Vilella, A., Zoli, M., Vandelli, M.A., Forni, F., Brain-targeted polymeric nanoparticles: in vivo evidences after different routes of administration in rodents. Nanomedicine UK 8 (2013), 1373–1383.
43. Valenza, M., Chen, J.Y., Di Paolo, E., Ruozi, B., Belletti, D., Ferrari Bardile, C., Leoni, V., Caccia, C., Brilli, E., Di Donato, S., Boido, M.M., Vercelli, A., Vandelli, M.A., Forni, F., Cepeda, C., Levine, M.S., Tosi, G., Cattaneo, E., Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice. EMBO Mol. Med. 7 (2015), 1547–1564.
44. Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, D.B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M.A., Biere, A.L., Curran, E., Burgess, T., Louis, J.C., Collins, F., Treanor, J., Rogers, G., Citron, M., Beta-Secretase cleavage of alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286 (1999), 735–741.
45. Vergoni, A.V., Tosi, G., Tacchi, R., Vandelli, M.A., Bertolini, A., Costantino, L., Nanoparticles as drug delivery agents specific for CNS: In vivo biodistribution. Nanomedicine 5 (2009), 369–377.
46. Vilella, A., Ruozi, B., Belletti, D., Pederzoli, F., Galliani, M., Semeghini, V., Forni, F., Zoli, M., Vandelli, M.A., Tosi, G., Endocytosis of nanomedicines: the case of glycopeptide engineered PLGA nanoparticles. Pharmaceutics 7 (2015), 74–89.
47. Virag, L., Robaszkiewicz, A., Rodriguez-Vargas, J.M., Oliver, F.J., Poly(ADP-ribose) signaling in cell death. Mol. Aspects Med. 34 (2013), 1153–1167.
48. Yallapu, M.M., Nagesh, P.K., Jaggi, M., Chauhan, S.C., Therapeutic applications of curcumin nanoformulations. AAPS J. 17 (2015), 1341–1356.
49. Yamamoto, Y., Gaynor, R.B., IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem. Sci. 29 (2004), 72–79.
50. Yang, F., Lim, G.P., Begum, A.N., Ubeda, O.J., Simmons, M.R., Ambegaokar, S.S., Chen, P.P., Kayed, R., Glabe, C.G., Frautschy, S.A., Cole, G.M., Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280 (2005), 5892–5901.